Navigation Links
Pathwork Diagnostics Collaborates With Guy's and St Thomas' on Tissue of Origin Test Validation in the UK

London Hospitals First in UK to Perform Study Utilizing Pathwork Tissue of Origin Test

SUNNYVALE, Calif., Dec. 9 /PRNewswire/ -- Pathwork Diagnostics, a molecular diagnostics company focused on oncology, announced today a collaboration with Guy's and St Thomas' NHS Foundation Trust in London. Guy's and St Thomas' will be the first hospitals in the United Kingdom to conduct a research study on the Pathwork(R) Tissue of Origin Test, which aids in the diagnosis of hard-to-identify tumors.

"We're extremely excited about entering into this partnership with Guy's and St Thomas' NHS Foundation Trust," said Deborah J. Neff, President and Chief Executive Officer of Pathwork Diagnostics. "In this study, pathologists and oncologists at Guy's and St Thomas' will not only be able to validate the test for use in their institution, but more importantly, soon be able to use information generated to help them determine the most effective, cancer-specific treatment regimen for hard-to-diagnose cases."

In the collaboration, Dr. Giuseppe Culora, the clinical director, and Dr. Eugene Halligan, the scientific director, are performing a proof-of-concept validation study. "Since patients with cancer of unknown primary have a very poor prognosis, we hope that with this novel diagnostic test our oncologists will have new information at their fingertips to guide treatment and be able to offer a better standard-of-care for our cancer patients," said Dr. Culora.

The Pathwork Tissue of Origin Test uses a microarray to measure the RNA expression pattern, comprising more than 1,500 genes, in the tumor and compares it to expression patterns of a panel of 15 known tumor types, representing 60 morphologies overall, to help determine the tumor's origin. Earlier this year, Pathwork became the first U.S.-based company to receive U.S. Food and Drug Administration (FDA) clearance for a molecular diagnostics test under the FDA's new IVDMIA (In Vitro Diagnostic Multivariate Index Assays) guidelines.

About Pathwork Diagnostics

Pathwork Diagnostics, Inc., based in Sunnyvale, Calif., develops and commercializes high-value molecular diagnostics for oncology. The company's first test to market - the Pathwork(R) Tissue of Origin Test - utilizes proprietary analytics and a companion Pathchip(R) microarray, which runs on the proven Affymetrix GeneChip(R) System. The test aids in determining a hard-to-identify tumor's origin so that standard-of-care, cancer-specific treatment can begin. The test is FDA-cleared as an in vitro diagnostic kit, while a functionally equivalent version of the test is also available through the CLIA-certified Pathwork(R) Diagnostics Laboratory. For more information, call 1.877.808.0006 or visit

About Guy's and St Thomas' NHS Foundation Trust

Guy's and St Thomas' provides around 3/4 million patient contacts in acute and specialist hospital services every year. As one of the biggest NHS Trusts in the UK, it employs over 9,000 staff. The Trust works in partnership with the Schools of Medicine, Dentistry, Nursing and Biomedical Sciences of King's College London and other Higher Education Institutes to deliver high quality education and research. Website:

King's College London and Guy's and St Thomas', King's College Hospital and South London and Maudsley NHS Foundation Trusts are working together to create a world-leading Academic Health Sciences Centre (AHSC). AHSC brings together an unrivalled range and depth of clinical and research expertise, spanning both physical and mental health. The combined strengths will drive improvements in care for patients, allowing them to benefit from breakthroughs in medical science and receive leading edge treatment at the earliest possible opportunity. For more information, visit

(C)2008 Pathwork Diagnostics, Inc. All rights reserved. Pathwork, Pathchip, Pathwork Diagnostics, and the Pathwork Diagnostics logo are trademarks or registered trademarks of Pathwork Diagnostics, Inc. Other names may be the trademarks of their respective owners.

SOURCE Pathwork Diagnostics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Studies Investigate Diagnostic Performance and Reproducibility of Pathwork Diagnostics Tissue of Origin Test
2. Pathwork Tissue of Origin Test Shows Potential to Aid in the Diagnosis of Cancer of Unknown Primary
3. Quest Diagnostics to Speak at the Bear Stearns Healthcare Conference
4. Pathway Diagnostics Announces Commercial Availability of SensiTrop(TM) HIV Co-receptor Tropism Assay
5. Hypertension Diagnostics Announces Fiscal Year 2007 Results
6. Foundation Venture Capital Group, LLC Invests in Start Up Committed to Breast Cancer Diagnostics
7. Meretek Diagnostics and Otsuka America Pharmaceutical, Inc. Announce Completion of Merger
8. Siemens Medical Solutions Diagnostics Announces the Release of the Rapidlab 1200 Series Version 2.0 Software
9. Virginia G. Piper Charitable Trust and Flinn Foundation launch molecular diagnostics initiative
10. HealthShares(TM) Announces Changes to the HealthShares(TM) Diagnostics and Composite Indexes
11. Optherion Licenses Worldwide Rights to Develop Age-Related Macular Degeneration Diagnostics Based on Chromosome 10 Genetic Variations
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... ... and SACC-USA through membership and leadership since 2008. Gary Bruce, President of PartnerTech ... . Gary has spent a significant amount of time in Sweden since joining ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... Center Enterprise Authorized Technology Provider (ATP) status from Cisco. This designation recognizes Tympani ... support Cisco Unified Contact Center solutions targeted to the high-end enterprise contact center ...
(Date:11/30/2015)... ... December 01, 2015 , ... The National ... 2015-2016 inductee into its VIP Woman of the Year Circle. She is recognized ... networking organization exclusively for professional women, boasting 850,000 members and over 200 operating ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... extremely stressful. At the VA Maryland Health Care System, the Caregiver Support ... patients. “Caregivers have a difficult job. Seventy-four percent report that their role ...
(Date:11/30/2015)... ... 30, 2015 , ... Thermi™, a world leader in thermistor-regulated ... ThermiRFR temperature controlled radiofrequency platform has received CE marking and may now be ... temperature as a clinical endpoint. The technology has been available in the ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... DUBLIN , Dec. 1, 2015 Research ... of the "Global Mouth Ulcer Treatment Market 2015-2019" ... --> --> According to the report, ... of the global population now affected by them. The ... hormonal imbalances, and tobacco smoking. Mouth disorders are also ...
(Date:11/30/2015)... , 1 décembre 2015 ... exposition et conférence d,Asie portant sur ... sur l,industrie manufacturière, se tiendra à ... 20 au 22 avril 2016. ... Photo - ...
(Date:11/30/2015)... , Nov. 30, 2015  QT Vascular Ltd., together ... together with its subsidiaries, TriReme Medical LLC and Quattro ... engaged in the design, assembly and distribution of advanced ... disease, is pleased to announce that a three-judge panel ... of Appeals for the Federal Circuit ("Federal Circuit") has ...
Breaking Medicine Technology: